Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 16/20 | 0.51 |
| ▸ | AXL | P30530 | 12/20 | 0.51 |
| ▸ | MET | P08581 | 2/20 | 0.50 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PRKCB | P05771 | 2/20 | 0.46 |
| ▸ | PRKCA | P17252 | 2/20 | 0.46 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.46 |
| ▸ | PRKCG | P05129 | 1/20 | 0.46 |
| ▸ | PRKCH | P24723 | 1/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13156526 | 1.00 | MERTK (0.51) | MERTKAXLMETTYRO3PKM | |
| SCHEMBL3103839 | 0.90 | NPC1 (0.56) | MERTKAXLMETTYRO3PRKCB | |
| SCHEMBL13156495 | 0.90 | NPC1 (0.56) | MERTKAXLMETTYRO3PRKCB | |
| SCHEMBL13181726 | 0.80 | L3MBTL1 (0.44) | ALOX5 | |
| SCHEMBL13156516 | 0.79 | L3MBTL1 (0.50) | ALOX5 | |
| SCHEMBL3101236 | 0.79 | L3MBTL1 (0.50) | ALOX5 | |
| SCHEMBL31291527 | 0.79 | L3MBTL1 (0.56) | ALOX5 | |
| SCHEMBL7864070 | 0.78 | CXCR1 (0.52) | PKM | |
| SCHEMBL7864067 | 0.78 | CXCR1 (0.52) | PKM | |
| SCHEMBL27701237 | 0.78 | KCNA5 (0.53) | MERTKAXLMETTYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799934-B2 | Intermediates (synthons) in the synthesis of pharmaceuticals such as oseltamivir and other products; treating the arizidine with the nucleophile in the presence of a biaryl phosphoric acid catalyst | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090030212-A1 | Enantioselective ring-opening of aziridines | UNIVERSITY OF SOUTH FLORIDA OF TAMPA | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030212-A1 | Enantioselective ring-opening of aziridines | AZI2, ITPA, ADORA2A | MERTK 4372/4885AXL 3222/4885MET 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.